🏛️ Verified NIH Record • Updated 2026-04-22
QTX3034 in Patients With KRAS G12D Mutation (NCT06227377)
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Quanta Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology/Oncology — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- UCLA Hematology/Oncology — Los Angeles, California
- Sarah Cannon Research Institute (SCRI) — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists — Sarasota, Florida
- Moffitt Cancer Center — Tampa, Florida
- NYU Langone Health — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Duke University — Durham, North Carolina
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- SCRI- Nashville — Nashville, Tennessee
- MD Anderson — Houston, Texas
- START San Antonio, LLC — San Antonio, Texas
- University of Utah, Huntsman Cancer Center — Salt Lake City, Utah
- NEXT Oncology Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (415) 599-3892
Email: clinicaltrials@quantatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.